SHP674

Developed for: acute lymphoblastic leukemia
Investigated by: ADIR, a Servier Group company · Kyowa Kirin, Inc. · Servier

today NCT04067518 · Ph 2

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT04067518	Oct 2019 → Feb 2021	acute lymphoblastic leukemia	Servier	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	SHP674	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04067518 ↗
Route	Intravenous	“IV (administered by 1 to 2 hours of drip infusion)” NCT04067518 ↗